

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gillian Daphne Elliott

Application No.: To be assigned

Filed: Herewith

For: VP22 PROTEINS AND USES THEREOF

Examiner: To be assigned

Date: July 10, 2003

Art Unit: To be assigned

**CERTIFICATE OF EXPRESS MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on July 10, 2003 as Express Mail Label No. EV339203223US in an envelope addressed to: MAIL STOP PATENT APPLICATION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA, 22313-1450.



William D. Noonan, M.D.  
Attorney for Applicant

**INFORMATION DISCLOSURE STATEMENT**  
**FOR CONTINUING APPLICATIONS**

MAIL STOP PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 are several English-language documents.

Applicant respectfully requests that such documents be listed as references cited on the issued patent.

The present application relies upon U.S. Patent Application No. 09/381,211, which was filed September 17, 1999, for an earlier filing date under 35 U.S.C. § 120. Furthermore, documents listed on the accompanying form PTO-1449 were disclosed to or cited by the Patent Office in the earlier U.S. application.

Copies of the documents listed on the accompanying form PTO-1449 that were cited by applicant in the earlier application need not be sent to the Patent Office pursuant to 37 C.F.R. § 1.98. However, applicant will furnish the Patent Office with such copies upon request.

Copies of documents listed on the accompanying form PTO-1449 that were cited by the Patent Office in the earlier application are enclosed.

Please charge any additional fees that may be required in connection with filing this Information Disclosure Statement, or credit any overpayment, to Deposit Account No. 02-4550.

A duplicate copy of this sheet is enclosed.

The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in Rule 56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan  
William D. Noonan, M.D.  
Registration No. 30,878

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Attorney Docket Number</b>	5759-66308
	<b>Application Number</b>	To be assigned
	<b>Filing Date</b>	Herewith
	<b>First Named Inventor</b>	Elliott
	<b>Art Unit</b>	To be assigned
	<b>Examiner Name</b>	To be assigned

### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		4,942,184	17 July 1990	Haugwitz et al.
		5,272,171	21 Dec 1993	Ueda et al.
		5,356,927	18 Oct 1994	Taraschi et al.
		5,621,001	15 Apr 1997	Canetta et al.
		5,631,278	20 May 1997	Taraschi et al.

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 89/08453		WIPO/PCT
		WO 90/10443		WIPO/PCT
		WO 93/02065		WIPO/PCT
		WO 93/14787		WIPO/PCT
		WO 94/12172		WIPO/PCT
		WO 97/05265		WIPO/PCT
		EP 0 473 326		EPC
		EP 0 505 047		EPC

EXAMINER  
SIGNATURE:

DATE  
CONSIDERED:

\* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Attorney D cket Number</b>	5759-66308
		<b>Application Number</b>	To be assigned
		<b>Filing Date</b>	Herewith
		<b>First Named Inventor</b>	Elliott
		<b>Art Unit</b>	To be assigned
		<b>Examiner Name</b>	To be assigned
<b>FOREIGN PATENT DOCUMENTS</b>			
		EP 0 524 093	EPC
		EP 0 537 905	EPC
		EP 0 558 959	EPC
		EP 0 584 001	EPC
<b>Examiner's Initials*</b>	<b>Cite No. (optional)</b>	<b>OTHER DOCUMENTS</b>	
		Benet et al., <i>The Pharmacological Basis of Therapeutics</i> , 8 <sup>th</sup> ed., pp. 3-266, McGraw Hill, Inc., New York, New York, 1990	
		De Arruda et al., <i>Cancer Research</i> 55(14):3085-3092, 1995	
		Dermer, <i>Bio/Technology</i> 12:320, 1994	
		Elliott et al., <i>J. Gen. Virol.</i> 73:723-726, 1992	
		Elliott et al., <i>Cell</i> 83:223-233, 1997	
		Jain, <i>Cancer Research and Metastasis Reviews</i> 9:253-266, 1990	
		Jain, <i>Science</i> 271:1079-1080, 1996	
		Mandelkow et al., <i>Neurobiology of Aging</i> 16(3):355-363, 1995	
		Marshall et al., <i>Nature Biotechnology</i> 15(3):205, 1997	
		Piperno et al., <i>J. Cell Biol.</i> 104:289-302, 1987	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	